Free Newsletter
Scientists: Gene action could be key to diabetes prevention, cure
PFKFB3, a gene often studied by cancer researchers, has been linked to the metabolic inflammation that leads to diabetes. And understanding how it works means scientists could find ways to prevent or cure diabetes, according to a study by Texas AgriLife Research appearing in the Journal of Biological Chemistry.
Dr. Chaodong Wu, AgriLife Research nutrition and food scientist at Texas A&M, worked with a team of researchers to identify the gene as a regulator for metabolism, which plays a vital role in the development of diabetes. Wu, who co-authored the study with the University of Minnesota's Dr. Yuqing Hou, says this information will help the team collaborate with nutritionists to identify what changes or supplements in a diet will activate the gene to prevent or stop the progression of diabetes.
Wu noted that while it is a major health concern in the U.S., obesity does not necessarily cause diabetes to develop. Rather, metabolic inflammation causes or exacerbates the disease, prompting the team to take a look at PFKFB3 to determine how the inflammation begins. "First we will need to identify what effective compounds will trigger the gene to regulate metabolism," Wu said. "Then we need to determine what combinations within foods are more effective."
- the study results published in Journal of Biological Chemistry are available here (.pdf)
- check out the Texas A&M story
Related Articles:
Scientists successfully treat diabetes with resveratrol
Experimental obesity drug has big impact on diabetes
Researcher: old drug may offer weapon against diabetes
NZ biotech to inject pig cells into diabetics
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




